Cargando…

Innate resistance of PD-1 blockade through loss of function mutations in JAK resulting in inability to express PD-L1 upon interferon exposure

Detalles Bibliográficos
Autores principales:	Shin, Daniel, Garcia-Diaz, Angel, Zaretsky, Jesse, Escuin-Ordinas, Helena, Hu-Lieskovan, Siwen, Palaskas, Nicolaos J, Hugo, Willy, Komenan, Marie Sara, Chmielowski, Bartosz, Cherry, Grace, Berent-Maoz, Beata, Graeber, Thomas G, Lo, Roger, Comin-Anduix, Begonya, Ribas, Antoni
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4649399/ http://dx.doi.org/10.1186/2051-1426-3-S2-P311

Ejemplares similares

Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
por: Garcia-Diaz, Angel, et al.
Publicado: (2017)

Characterization of Postinfusion Phenotypic Differences in Fresh Versus Cryopreserved TCR Engineered Adoptive Cell Therapy Products
por: Nowicki, Theodore S., et al.
Publicado: (2018)

Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma
por: Homet Moreno, Blanca, et al.
Publicado: (2015)

Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma
por: Atefi, Mohammad, et al.
Publicado: (2015)

Tremelimumab: research and clinical development
por: Comin-Anduix, Begoña, et al.
Publicado: (2016)

What does PD-L1 positive or negative mean?
por: Ribas, Antoni, et al.
Publicado: (2016)

Modulation of Cell Signaling Networks after CTLA4 Blockade in Patients with Metastatic Melanoma
por: Comin-Anduix, Begoña, et al.
Publicado: (2010)

Immunotherapy resistance driven by loss of NY-ESO-1 expression in response to transgenic adoptive cellular therapy with PD-1 blockade
por: Frankiw, Luke, et al.
Publicado: (2023)

Global alteration of T-lymphocyte metabolism by PD-L1 checkpoint involves a block of de novo nucleoside phosphate synthesis
por: Palaskas, Nicolaos Jay, et al.
Publicado: (2019)

Distinct immunological mechanisms of CTLA-4 and PD-1 blockade revealed by analyzing TCR usage in blood lymphocytes
por: Robert, Lidia, et al.
Publicado: (2014)

High response rate to PD-1 blockade in desmoplastic melanomas
por: Eroglu, Zeynep, et al.
Publicado: (2018)

Reversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT/mTOR Pathway
por: Atefi, Mohammad, et al.
Publicado: (2011)

Wound healing with topical BRAF inhibitor therapy in a diabetic model suggests tissue regenerative effects
por: Escuin-Ordinas, Helena, et al.
Publicado: (2021)

PET imaging to non-invasively study immune activation leading to antitumor responses with a 4-1BB agonistic antibody
por: Escuin-Ordinas, Helena, et al.
Publicado: (2013)

Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma
por: Lassen, Amanda, et al.
Publicado: (2014)

Cutaneous wound healing through paradoxical MAPK activation by BRAF inhibitors
por: Escuin-Ordinas, Helena, et al.
Publicado: (2016)

CTLA4 blockade increases Th17 cells in patients with metastatic melanoma
por: von Euw, Erika, et al.
Publicado: (2009)

Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma
por: Wong, Deborah JL, et al.
Publicado: (2014)

Erratum to: Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma
por: Wong, Deborah JL, et al.
Publicado: (2015)

A kinetic investigation of interacting, stimulated T cells identifies conditions for rapid functional enhancement, minimal phenotype differentiation, and improved adoptive cell transfer tumor eradication
por: Zhou, Jing, et al.
Publicado: (2018)

Inhibition of colony stimulating factor-1 receptor improves antitumor efficacy of BRAF inhibition
por: Mok, Stephen, et al.
Publicado: (2015)

PD-1/PD-L1 signaling in JIA synovial regulatory T cell function
por: de Roock, Sytze, et al.
Publicado: (2011)

Exosomes as a predictor tool of acquired resistance to melanoma treatment
por: Goedert, Lucas, et al.
Publicado: (2014)

Real-world experience with elective discontinuation of PD-1 inhibitors at 1 year in patients with metastatic melanoma
por: Pokorny, Rebecca, et al.
Publicado: (2021)

PD-1 blockade induces responses by inhibiting adaptive immune resistance
por: Tumeh, Paul C., et al.
Publicado: (2014)

Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2
por: Luo, Na, et al.
Publicado: (2018)

Safety and clinical activity of PD-L1 blockade in patients with aggressive recurrent respiratory papillomatosis
por: Allen, Clint T., et al.
Publicado: (2019)

Association of Tumor Mutational Burden and Immune Gene Expression with Response to PD-1 Blockade by Sasanlimab Across Tumor Types and Routes of Administration
por: Hu-Lieskovan, Siwen, et al.
Publicado: (2021)

Natural Killer T Cells in Advanced Melanoma Patients Treated with Tremelimumab
por: Ibarrondo, F. Javier, et al.
Publicado: (2013)

Real‐world survival of patients with advanced BRAF V600 mutated melanoma treated with front‐line BRAF/MEK inhibitors, anti‐PD‐1 antibodies, or nivolumab/ipilimumab
por: Moser, Justin C., et al.
Publicado: (2019)

Inability and Obligation in Moral Judgment
por: Buckwalter, Wesley, et al.
Publicado: (2015)

Inability to Culture Pneumocystis jirovecii
por: Liu, Yueqin, et al.
Publicado: (2018)

Syncope and the Inability to Move: Was It the Magnesium?
por: Perkins, David R, et al.
Publicado: (2023)

Detection of antibody therapy-induced anti-tumor immune responses using anti-CD8 immuno-pet
por: Tavare, Richard, et al.
Publicado: (2015)

Beyond the immediate tumor microenvironment: distinct T cell phenotype and function of tumor-adjacent healthy breast tissue associated with regional metastasis in breast cancer
por: Guo, Yi, et al.
Publicado: (2014)

EGCG Inhibits Tumor Growth in Melanoma by Targeting JAK-STAT Signaling and Its Downstream PD-L1/PD-L2-PD1 Axis in Tumors and Enhancing Cytotoxic T-Cell Responses
por: Ravindran Menon, Dinoop, et al.
Publicado: (2021)

Pelvic Abscess with Presentation as Inability to Ambulate
por: Damer, Sarah A.
Publicado: (2017)

Infant with inability to abduct left eye
por: Dodderer, Joshua K., et al.
Publicado: (2021)

Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations
por: Niehr, Franziska, et al.
Publicado: (2011)

Overcoming PD-1 Blockade Resistance with CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients with Metastatic Melanoma
por: Ribas, Antoni, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_q9nt4p7olq5qcgv2dk1h5u17ou